GILD

GILD

USD

Gilead Sciences Inc. Common Stock

$118.840-5.050 (-4.076%)

实时价格

Healthcare
Drug Manufacturers - General
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$123.890

最高价

$124.000

最低价

$117.540

成交量

6.29M

公司基本面

市值

147.6B

所属行业

Drug Manufacturers - General

国家/地区

United States

交易统计

平均成交量

6.96M

交易所

NMS

货币

USD

52周价格范围

最低价 $86.08当前价 $118.840最高价 $124.61

相关新闻

BusinessWire

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: UBS Global Healthcare Conference on Monday, November 10 at 11:00 AM Eastern

查看更多
Gilead Sciences to Present at Upcoming Investor Conferences
Analyst Upgrades

Truist Securities Reiterates Buy on Gilead Sciences, Raises Price Target to $145

Truist Securities analyst Asthika Goonewardene reiterates Gilead Sciences with a Buy and raises the price target from $127 to $145.

查看更多
Truist Securities Reiterates Buy on Gilead Sciences, Raises Price Target to $145
BusinessWire

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

– Updated Results from Phase 2 Pivotal iMMagine-1 Study of Anito-cel for Relapsed/Refractory Multiple Myeloma to be Presented Orally – – New Findings Reinforce Yescarta's® Curative Potential as Second-Line

查看更多
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
Analyst Upgrades

JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $150

JP Morgan analyst Chris Schott maintains Gilead Sciences with a Overweight and raises the price target from $145 to $150.

查看更多
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $150
Analyst Upgrades

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026.

查看更多
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Analyst Upgrades

RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $105

RBC Capital analyst Brian Abrahams maintains Gilead Sciences with a Sector Perform and raises the price target from $100 to $105.

Analyst Upgrades

Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $135 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences with a Overweight and maintains $135 price target.